NCT04879329 2026-04-21
A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2
Seagen Inc.
Phase 2 Recruiting
Clinical Trials
15 trialsNCT05911295 2026-04-20
Disitamab Vedotin With Pembrolizumab vs Chemotherapy in Previously Untreated Urothelial Cancer Expressing HER2
Seagen Inc.
Phase 3 Active not recruiting
NCT07474064 2026-03-17
Probiotics Combined With Targeted Therapy Plus Immunotherapy in Bladder-Preserving Setting for Patients With MIBC
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 2 Not yet recruiting
NCT06957561 2025-05-04
DIVON
Sun Yat-sen University
Phase 1/2 Not yet recruiting
NCT06663007 2024-10-29
RC48 Monotherapy or Combination With Envafolimab for CDK12 Alterations mCRPC With Standard Treatment Failure
Tianjin Medical University Second Hospital
Phase 1/2 Recruiting
NCT06187506 2024-07-12
Disitamab Vedotin Combined With BCG Therapy in HER2-expressing High-risk Non-muscle Invasive Bladder Cancer
Fudan University
Phase 2 Recruiting
NCT06378242 2024-07-11
To Evaluate the Safety, Efficacy, and Pharmacokinetics of Intravesical Instiliations of Disitamab Vedotin in Patients With High-risk Non-muscular Invasive Bladder Cancer (NMIBC) That Express HER2
RemeGen Co., Ltd.
Phase 1/2 Recruiting
NCT06227156 2024-05-23
Disitamab Vedotin in the Treatment With HER2- Expression, Subjects With Locally Advanced or Metastatic Castration-resistant Prostate Cancer
RemeGen Co., Ltd.
Phase 2 Recruiting
NCT05302284 2023-12-18
A Study of RC48-ADC Combined With Toripalimab For First-line Treatment of Urothelial Carcinoma
RemeGen Co., Ltd.
Phase 3 Recruiting
NCT05957757 2023-08-31
RC48 Combined With Tislelizumab for Bladder Sparing Treatment in NMIBC With BCG Treatment Failure and HER2 Expression
RenJi Hospital
Phase 2 Recruiting
NCT05979740 2023-08-31
RC48 Combined With Toripalimab and Radiotherapy for Bladder Sparing Treatment in MIBC
RenJi Hospital
Phase 2 Unknown
NCT05912205 2023-06-22
Disitamab Vedotin Combined With Radiotherapy for Bladder Preservation
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Phase 2 Not yet recruiting
NCT05723991 2023-02-13
Study of Disitamab Vedotin Combined With Gemcitabine in Neoadjuvant Treatment of Urothelial Carcinoma
Tongji Hospital
Phase 4 Unknown
NCT05488353 2022-08-04
A Clinical Study of Disitamab Vedotin for Injection Combined With Penpulimab Injection in Neoadjuvant Therapy for Patients With HER2-expressing Cisplatin-intolerant cT2-T4aNxM0 Bladder Urothelial Carcinoma
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 4 Not yet recruiting
NCT05016973 2021-08-23
A Clinical Study of RC48-ADC Combined With Triplizumab For Treatment of Myometrial Invasive Bladder Cancer
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Phase 2 Unknown